← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Bedrock Therapeutics, Inc.
Chapel Hill, NC
$3,473,311
Total funding
7
Grants
Funding over time
peak $1.4M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,473,311 · 7
By mechanism
R42$1,769,317 · 1
R41$1,703,994 · 6
Investigators at Bedrock Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Prevention of corneal transplant rejection using AAV-BDRK-401 therapy$975,387
R42 · FY2024 · EY
Prevention of corneal transplant rejection using AAV-BDRK-401 therapy$793,930
R42 · FY2025 · EY
Immunosuppressive Gene Therapy for Ocular Graft vs Host Disease$328,150
R41 · FY2021 · EY
Vector mediated anti-vascular and anti-inflammatory therapy for AMD$310,952
R41 · FY2025 · EY
Intramuscular Administration of AAV Vectors Encoding soluble PD-L1 for Rheumatoid Arthritis Treatment$304,502
R41 · FY2025 · AR
Rational design of AAV vectors with human hepatocyte tropism and neutralizing antibody evasion$261,080
R41 · FY2022 · DK
Develop humanized AAV vectors for liver targeting and neutralizing antibody evasion$249,310
R41 · FY2020 · HL
Prevention of corneal transplant rejection using AAV-HLA-G combination therapy$171,923
R41 · FY2021 · EY
Prevention of corneal transplant rejection using AAV-HLA-G combination therapy$78,077
R41 · FY2020 · EY